UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000043321
Receipt No. R000049458
Scientific Title A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level: Randomized double-blind placebo-controlled trial
Date of disclosure of the study information 2021/02/15
Last modified on 2021/02/14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level
Acronym A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level
Scientific Title A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level: Randomized double-blind placebo-controlled trial
Scientific Title:Acronym A clinical study for evaluating the efficacy of test food on the suppression of the elevation of postprandial blood glucose level
Region
Japan

Condition
Condition Healthy adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the efficacy of test food intake on the suppression of the elevation of postprandial blood glucose after meal.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes - Blood glucose
*Measure at before ingestion and 15, 30, 45, 60, 90, and 120 minutes after ingestion.
- Area Under the Curve
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 1)Test food + rice 200 g, single ingestion
2)Wash out for 1 week
3)Placebo food + rice 200 g, single ingestion
Interventions/Control_2 1)Placebo food + rice 200 g, single ingestion
2)Wash out for 1 week
3)Test food + rice 200 g, single ingestion
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria 1) Japanese male and female aged 20-64 years old at the time of the informed consent
2) Subjects whose fasting blood glucose level is less than 126 mg/dL or two-hour blood glucose level after 75 g glucose loading is less than 200 mg/dL at the screening test.
3) Subject who has understood the purpose of the study, and agreed to participate it by signing the written informed consent.
Key exclusion criteria 1)Subject who is considered as a diabetes by a doctor.
2)Subject who is taking medication or under medical treatment.
3)Subject who is under exercise therapy or dietetic therapy.
4)Subject who has an allergy for test food.
5)Subject who has or had a history of either medicine or alcohol dependence syndrome.
6)Subject who has or had a history of mental illness(depression) or sleep disturbance.
7)Subject who is on a night-shift or is a shift worker.
8)Subject whose lifestyle is extremely irregular.
9)Subject who has an unbalanced diet.
10)Subject who is current disease or history of brain disorder, cancer, immunity disorder, diabetes, liver disease(hepatitis), kidney disease, serious disease such as heart disease, thyroid disease, adrenal disease, other metabolic diseases.
11)Subject who is use health foods, supplements, and medicines that may affect diabetes.
12)Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
13)Subject who has blood drawn 200 mL within the past 1 months or 400 mL within the past 3 months from the day of the consent acquisition.
14)Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating.
15)Subject who can't keep the daily records.
16)Subject who is judged as an inappropriate candidate according to the screening data.
17)Subject who is considered as an inappropriate candidate by the doctor in charge.
Target sample size 30

Research contact person
Name of lead principal investigator
1st name Atsushi
Middle name
Last name Yamatsu
Organization Pharma Foods International Co., Ltd.
Division name Research and Development
Zip code 615-8245
Address 1-49, Goryo-ohara, nishikyo-ku, Kyoto city, Kyoto, Japan
TEL 075-748-9829
Email a-yamatsu@pharmafoods.co.jp

Public contact
Name of contact person
1st name Daisuke
Middle name
Last name Ochitani
Organization HUMA R&D CORP
Division name Clinical Development Division
Zip code 108-0014
Address Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
TEL 03-3431-1260
Homepage URL
Email ochitani@huma-rd.co.jp

Sponsor
Institute Pharma Foods International Co., Ltd.
Institute
Department

Funding Source
Organization Mitsubishi Corporation Life Sciences Limited
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization the ethics committees of Yoga Allergy Clinic
Address 4-32-16, Yoga, Setagaya-ku, Tokyo, Japan
Tel 03-5491-4478
Email jim@medipharma.co.jp

Secondary IDs
Secondary IDs YES
Study ID_1 FH19-001
Org. issuing International ID_1 HUMA R&D CORP
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions とうきょうスカイツリー駅前内科

Other administrative information
Date of disclosure of the study information
2021 Year 02 Month 15 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2021 Year 01 Month 29 Day
Date of IRB
2021 Year 02 Month 12 Day
Anticipated trial start date
2021 Year 02 Month 15 Day
Last follow-up date
2021 Year 07 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2021 Year 02 Month 14 Day
Last modified on
2021 Year 02 Month 14 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049458

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.